Euro Foscan study to boost biolitec's PDT (photodynamic therapy) drug
This article was originally published in Clinica
Executive Summary
German photodynamic therapy company biolitec last week successfully ended a five-year-plus study of its Foscan PDT light-activated drug for head and neck tumours, which was required by the European Medicines Evaluation Agency (EMEA). Jena-based biolitec says the therapy should now be able to retain its approval. Furthermore, completion of the study will lead to "considerably greater" market penetration for the photodynamic therapy (PDT) drug, for which the company is now also preparing to embark on approval negotiations with the US FDA.